Abstract: The invention relates to novel variants of a protease derived from Nocardiopsis sp. (SEQ ID NO: 1) and closely related proteases, as well as their pharmaceutical use. The variants show improved performance in the treatment of pancreatic exocrine insufficiency (PEI). The variants may be combined with a lipase and/or an amylase. Other examples of medical indications are: Treatment of digestive disorders, pancreatitis, cystic fibrosis, diabetes type I, and/or diabetes type II.

Abstract: Described herein are pyrimidine dimer-specific glycosylase (PDG) polypeptides and methods of use for repair of damaged DNA. The PDG polypeptides comprise amino acid sequence from T4-PDG, CV-PDG or engineered mutants thereof. The PDG polypeptides further comprise a targeting sequence, such as a nuclear targeting sequence or a mitochondrial targeting sequence, and a protein transduction domain. The mutant PDG polypeptides described herein retain at least some catalytic activity while exhibiting reduced cytotoxicity in wild-type cells.

Abstract: The present invention provides a method for prophylaxis and therapy of infectious diseases caused by microorganisms present in biofilms adherent to cell surfaces comprising the step of administering to an individual in need thereof a composition comprising a combination of at least one compound chosen from the group of peroxidase, lactoferrin, lactoferrin peptides, lysozyme and immunoglobulins and at least one growth factor.

Abstract: A method of identifying a compound capable of correcting an impaired enzymatic activity of a mutant glucocerebrosidase molecule, the method comprising: (a) obtaining a first set of structure coordinates, the first set of structure coordinates defining a 3D structure of a glucocerebrosidase molecule capable of displaying normal enzymatic activity or a portion thereof; (b) computationally generating using the first set of structure coordinates a second set of structure coordinates, the second set of structure coordinates defining a predicted 3D structure of the mutant glucocerebrosidase molecule or a portion thereof; and (c) computationally identifying, using the second set of structure coordinates, a compound capable of interacting with the mutant glucocerebrosidase molecule in such a way as to correct the impaired enzymatic activity thereof, thereby identifying the compound capable of correcting the impaired enzymatic activity of the mutant glucocerebrosidase molecule.

Abstract: A dry treatment mixture is provided including: a quantity of a dry formulation of a salt; and a quantity of a dry formulation of lysozyme. The salt preferably is sea salt. The dry treatment mixture preferably additionally includes a dry formulation of lactoferrin. A method of producing a dry treatment mixture preferably includes the steps of: providing a quantity of a dry formulation of salt in one of powder form and granular form; providing a quantity of a dry formulation of lysozyme; and mixing the quantity of a dry formulation of salt and the quantity of a dry formulation of lysozyme together to form a dry treatment mixture. The method optionally includes the yet additional step of compressing a quantity of the mixture in a mold to form a mixture pill or of encapsulating the quantity of the mixture in a capsule for oral administration, or impregnating a bandage with the mixture for topical administration.

Abstract: The present invention encompasses methods and compositions for alleviating pruritis. The compositions may comprise an analgesic agent.

Abstract: A composition of lysozyme and a pharmaceutically acceptable carrier is active against the papilloma virus in both humans and animals. The composition can be used to treat women suffering from cervical cancer. The composition can also be used to treat cows and horses suffering sarcoids.

Abstract: The present invention provides for compositions and methods for treating, ameliorating or preventing a lysosomal storage disease by administering to a patient suffering from a lysosomal storage disease a P97 conjugated with an enzyme which is capable of transportation into the lysosomes of cells on either sides of the blood brain barrier.

Abstract: The present invention relates to methods for modulating the migratory activity of cells expressing CD38 for the treatment of disorders including, but not limited to, inflammation, ischemia, asthma, autoimmune disease, diabetes, arthritis, allergies, infection with pathogenic organisms, such as parasites, and transplant rejection. Such cells include, for example, neutrophils, lymphocytes, eosinophils, macrophages and dentritic cells. The invention further relates to drug screening assays designed to identify compounds that modulate the ADP-ribosyl cyclase activity of CD38 and the use of such. compounds in the treatment of disorders involving CD38 modulated cell migration. Additionally, the invention relates to the isolation and characterization of a CD38 homologue from the parasitic flatworm, Schistosoma mansoni.

Abstract: A fragment of lysozyme which contains a minimum nine amino acid sequence with antiviral, anti-tumor and bactericidal activities but lacking muramidase activity is provided. The invention also relates to pharmaceutical compositions containing this fragment and methods for treating HIV infection or for inhibiting tumor growth using this fragment as an active ingredient.

Abstract: The present invention provides a pharmaceutical composition comprising a protein having ?-galactosidase activity for treating Fabry disease, which causes no allergic side effect, which is highly stable in blood (plasma) and which can readily be taken up by a cell of an affected organ. The pharmaceutical composition for treating Fabry disease of the invention comprises, for example, a protein which acquires an ?-galactosidase activity through alteration of the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.

Abstract: The invention relates, in part, to improved methods of administering ?-galactosidase A for the treatment of ?-galactosidase A deficiencies including Fabry disease.

Abstract: The invention provides compositions and methods for enhancing clearance of coagulation factors {e.g., VWF) and platelets from the blood stream of a patient in need thereof. The methods comprise administering to the patient a therapeutically effective amount of an agent that increases clearance of coagulation factors or platelets. Such an agent can be, for example, a neuraminidase.

Abstract: A cosmetic treatment system is provided having ingredients that may prevent signs of aging, improve the aesthetic appearance of skin, and promote recovery from environmental stresses. The composition includes natural ingredients, including at least one ingredient or extract from rosemary; at least one ingredient or extract from Centella, Echinacea, Alpinia or mixtures thereof; a DNA repair enzyme; and at least one pharmaceutically or cosmetically acceptable vehicle. The treatment system may further include a patch for applying the cosmetic ingredients and/or a packaging system for holding the components of the cosmetic treatment system.

Abstract: The invention relates to the use of ethylenediamine tetraacetic acid (EDTA) and its derivatives, i.e. its salts and complexes for prevention and treatment of bacterial intestinal diseases of pigs and for increasing the effects of antibiotics exerted in such diseases. The invention also relates to compositions for animal husbandry, i.e. to veterinary compositions and to feeds and drinks which can be consumed by pigs, comprising EDTA or its derivatives.

Abstract: The present invention incorporates medicaments in the empty hard capsule shells (body and cap). The medicament is either physically/molecularly distributed and/or chemically bound to the polymer matrix of the capsule shell composition. Other medicaments in the form of drug-loaded matrices (powders, granules, beads, pellets, mini-tablets, and mini-capsules) can be filled in the drug-loaded empty, hard capsule shells. The same capsule dosage form contains medicaments in the core matrix and in the shell.

Abstract: The present invention relates to compositions and methods for the reduction of atherosclerotic plaques and the decrease in the level of total serum cholesterol, triglycerides, serum LDL cholesterol, and serum HDL cholesterol.

Abstract: The present invention provides methods for preventing and/or treating lysosomal storage disorders using 5-(fluoromethyl)piperidine-3,4-diol, 5-(chloromethyl)piperidine-3,4-diol, or a pharmaceutically acceptable salt, solvate, or prodrug thereof, or any combination of two or more thereof. In particular, the present invention provides methods for preventing and/or treating Gaucher's disease.

Abstract: The present invention provides galacto-oligosaccharide compositions that preferentially stimulate growth of specific Bifidobacterium species and subspecies.

Abstract: This document provides methods and materials related to reducing biofilms. For example, enzymes (e.g., glycosyl hydrolases), nucleic acid molecules encoding enzymes, host cells containing nucleic acid encoding enzymes, and methods for using enzymes to reduce biofilms and infections associated with biofilms are provided.

Abstract: Methods of treating glycogen storage disease type II, by administering acid ?-glucosidase, are described, as are compositions for use in treatment of glycogen storage disease type II.

Abstract: The present invention includes compositions and methods for preparing micron-sized or submicron-sized particles by dissolving a water soluble effective ingredient in one or more solvents; spraying or dripping droplets solvent such that the effective ingredient is exposed to a vapor-liquid interface of less than 50, 100, 150, 200, 250, 200, 400 or 500 cm?1 area/volume to, e.g., increase protein stability; and contacting the droplet with a freezing surface that has a temperature differential of at least 30° C. between the droplet and the surface, wherein the surface freezes the droplet into a thin film with a thickness of less than 500 micrometers and a surface area to volume between 25 to 500 cm?1.

Abstract: The present invention is directed to novel food products, e.g., nutritional food products and infant formula, which contain one ore more enzymes selected from lipase, protease, and amylase that have been formulated/stabilized to have sustained stability in an aqueous medium. Such formulations are intended to provide a greater degree of compliance based on their ability to be incorporated into aqueous media while avoiding unstable breakdown of the enzyme and large overdosing due to expected breakdown when exposed to an aqueous environment, including saliva. Further described in the invention are additives packaged with instructions for combination with an aqueous medium, and instructions for the administration of the resulting mixture to a subject. In certain embodiments, enzyme insufficient patients, e.g., infants and elderly persons, would find particular benefit from the food products described herein.

Abstract: A stable preparation of digestive/pancreatic enzymes which can be readily formed into a dosage formulation is provided as a treatment of pancreatic insufficiency in persons having cystic fibrosis. The dosage formulation can be administered either by an oral preparation including, but not limited to, a microcapsule, mini-capsule, time released capsule, sprinkle or other methodology. A further object of this invention is to provide a stabilized preparation of a combination medicant which resists degradation by light, heat, humidity or association with commonly used excipients.

Abstract: The present invention provides viscoelastic gel compositions comprising microparticles which are capable of interacting with each other in a non-ionic manner, thus forming a gel network. The gel compositions may incorporate active agents and provide controlled release of such agents. The compositions are useful as injectable depot formulations of therapeutic compounds. In a further aspect, microparticles capable of gel formation in an aqueous environment are provided, as well as method of making viscoelastic gels based on the interaction of uncharged microparticles. Moreover, the invention discloses kits for making viscoelastic gel compositions and uses thereof.

Abstract: A method of preparing porous microparticles comprises the steps of combining one or more organic compounds with a volatile system, and drying the system thus formed to provide substantially pure porous microparticles of the organic compound or composite porous microparticles of combinations of organic compounds. Organic compounds used in the method may be one or more of a bioactive, a pharmaceutically acceptable excipient, a pharmaceutically acceptable adjuvant or combinations thereof. The invention also relates to porous microparticles produced by such a method, and pharmaceutical compositions comprising such porous microparticles.

Abstract: The present invention relates to compositions and methods for promoting healing of cutaneous, mucosal and/or mucocutaneous lesions associated with the presence of a mycoplasma and one or more non-mycoplasma microorganisms.

Abstract: The invention relates to chimeric polypeptides comprising a lysosomal peptide fused or conjugated to at least one cell-penetrating peptide (CPP). Also provided by the invention are methods for treating a subject suffering from lysosomal storage disorders (LSD).

Abstract: Methods of treating an arthritic joint of a subject, including administering a pharmaceutical composition by injection into the arthritic joint, wherein the composition includes an anthocyanin or anthocyanidin, glucose, and a pharmaceutically acceptable carrier.

Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.

Abstract: The invention provides methods and devices for the delivery of therapeutic or biologically active agents to tissue, for example by facilitating the transport of said agents through the skin of a human or animal. Therapeutic agents include various botulinum neurotoxin (BoNT) and other biologically active agents, which can be delivered across the skin and into the dermis using multiple strategies including microneedle drug delivery, transport moieties, or penetration enhancers such as extracellular matrix-digestive enzymes.

Abstract: Disclosed herein are polypeptide multilayer films wherein a therapeutic agent is covalently linked to a first layer polypeptide. An advantage of such attachment is that the linked therapeutic agent can be controllably released from the multilayer film into the environment of the film upon the addition of a suitable stimulus. An advantage of the disclosed films and methods is enablement of environmentally-stimulated release under specific conditions.

Abstract: The present invention provides novel hydroxy piperidine (HP) derivatives having (i) a positive charge at the position corresponding to the anomeric position of a pyranose ring; (ii) a short, flexible linker emanating from the corresponding position of the ring oxygen in a pyranose; and (iii) a lipophilic moiety connected to the linker and pharmaceutically acceptable salts thereof. The linker can be absent if the lipophilic moiety corresponds to a hydrocarbon chain with a linear length of 6 or more carbons. The present invention further provides a method for treating individuals having Gaucher disease by administering the novel HP derivative as “active-site specific chaperones” for the mutant glucocerebrosidase associated with the disease.

Abstract: Specific nitroprotein biomarkers may be used as prognostic and diagnostic tools for COPD. Identification of certain specific nitroprotein biomarkers allows the development of targeted therapies aimed at prevention and treatment of COPD.

Abstract: Provided herein methods for determining whether a subject, particularly a human subject, is at risk of developing, having, or experiencing a complication of cardiovascular disease, and methods of treating subjects who are identified by the current methods of being at risk for cardiovascular disease. In one embodiment, the method comprises determining levels of one or more oxidized apolipoprotein A-I related biomolecules in a bodily sample from the subject. Also, provided are kits and reagents for use in the present methods. Also provided are methods for monitoring the status of cardiovascular disease in a subject or the effects of therapeutic agents on subjects with cardiovascular disease. Such method comprising determining levels of one or more oxidized apolipoprotein A-I related molecules in bodily samples taken from the subject over time or before and after therapy.

Abstract: The present invention discloses novel synergistic anthelmintic compositions used for prevention and treatment of gastrointestinal nematodes comprising combination of therapeutically effective amount of ginger extract with proteolytic enzyme and fibre degrading enzymes. The novel anthelmintic compositions provide synergistic effect at comparatively lower doses which are affordable and impart minimal/no side effect on general health as well as milk yield of dairy animals.

Abstract: The present invention provides, as an enzyme which can be used for enzyme replacement therapy for Fabry disease, a protein having ?-galactosidase activity, which shows no allergic adverse side effect, shows a high stability in blood, and can be easily incorporated into a cell of an affected organ. The protein of the present invention is a protein which has acquired ?-galactosidase activity by changing the structure of the active site of wild-type human ?-N-acetylgalactosaminidase.

Abstract: The present invention provides a polypeptide therapeutic agent, useful in enzyme replacement therapy, with increased therapeutic benefits for the central nervous system. The invention provides a method of enhancing the effect of a polypeptide or protein on the central nervous system by the attachment of a short acidic amino acid sequence. Specifically the inventors disclose the attachment of a 4-15 acidic amino acid sequence to human ?-glucuronidase by construction of a fusion protein. This molecule is useful in the treatment of type VII mucopolysaccharidosis when administered to a patient.

Abstract: Oral insulin formulations and processes for preparing oral insulin formulations are provided.

Abstract: Methods of modulating uptake of extracellular lysosomal enzymes by administering a pharmaceutical agent and methods of treating a lysosomal storage disease (such as Gaucher disease, Pompe disease, Fabry disease or Niemann-Pick disease) or enhancing enzyme replacement therapy or gene therapy, comprising administering a pharmaceutical agent such as dexamethasone, glucose or insulin, are provided.

Abstract: The present invention provides a composition for forming a compressed solid dosage form that is a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22. Also included are solid dosage forms made from a free-flowing compressible admixture of simethicone, an adsorbant, and an optional active agent, wherein the weight ratio of simethicone to adsorbent is at least 1:2.22.

Abstract: The invention provides use of an EndoS polypeptide, or a polynucleotide encoding an EndoS polypeptide, in the manufacture of a medicament for the treatment or prevention of a disease or condition mediated by IgG antibodies.

Abstract: The invention provides a method of determining the likelihood that a smoker will or will not develop chronic obstructive pulmonary disease (COPD) by obtaining a sample from the smoker, analyzing the sample for the expression of a set of biomarkers associated with COPD, and comparing the expression pattern determined in the sample with a standard expression pattern to determine the likelihood that the smoker will or will not develop COPD. The invention further provides a composition, a method of treatment, and methods of determining the efficacy of treatment for COPD.

Abstract: A method for producing a flowing silica composition including a sol-gel transfer, where redispersion is carried out. The redispersion includes adding, after having reached gel point of the sol-gel transfer, liquid into the gel formed by the sol-gel transfer, and the addition being made within a sufficiently short time period after reaching the gel point, to result, after mixing of the gel and the liquid, in a rheologically homogenous flowing silica composition, which is and remains injectable as such, or by short stirring <30 s, through a thin 22 G needle. Also disclosed are flowing silica compositions and gels obtainable by methods of the invention, and uses of flowing silica compositions.

Abstract: The present application provides a method for treating Pompe disease in a subject in need thereof, that includes a method of administering to the subject a GAA enzyme in combination with an ASSC for the GAA enzyme. The present application also provides methods for increasing the in vitro and in vivo stability of a GAA enzyme formulation.

Abstract: The present invention relates to novel active substance compositions for plant protection in the form of finely divided active-substance-containing particles which compositions comprise a) at least one plant protectant; b) at least one polymer P which is not soluble in water and which is degradable by enzymatic hydrolysis, in an amount of at least 20% by weight based on the total amount of the components of the active-substance-comprising particles, and c) at least one hydrolase (EC 3), where at least 90% by weight of the active substance-containing particles of the active substance composition do not exceed a diameter of 500 ?m (D90-value) and where components a), b) and c) account for at least 30% by weight of the active substance particles. The invention also relates to a process for their preparation, and to the use of the active substance compositions for the treatment of plants, soils and of seed.

Abstract: The co-administration of glufosfamide and a glucose lowering drug other than insulin is efficacious in cancer treatment.

Abstract: A therapeutic composition for the treatment of the symptoms of prion diseases and the method for preparing the therapeutic agents is disclosed. The therapeutic composition is a stable pharmaceutical composition comprising one or more digestive and/or pancreatic enzymes. The therapeutic composition may be manufactured by a variety of encapsulation technologies. Delivery of the therapeutic composition may be made orally, through injection, by adherence of a medicated patch or other method. Further, a method of using fecal chymotrypsin level as a biomarker for the presence of a prion disease, or the likelihood of an individual to develop a prion disease is disclosed.

Abstract: The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient.

Abstract: This invention relates to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, polynucleotides encoding these polypeptides, and methods of making and using these polynucleotides and polypeptides. In some embodiments, the invention is directed to polypeptides having aldolase activity, including pyruvate activity such as, without limitation, HMG and/or KHG aldolase activity, including thermostable and thermotolerant activity, and polynucleotides encoding these enzymes, and making and using these polynucleotides and polypeptides. The polypeptides in accordance with the invention can be used in a variety of pharmaceutical, agricultural and industrial contexts.